YD Bio (YDES) CEO Dr. Ethan Shen Buys 18,378 Shares

What Happened

• Dr. Ethan Shen, CEO and Director of YD Bio Ltd (YDES), reported a purchase of 18,378 ordinary shares on 2026-09-04. The filing shows a weighted average price of $3.67 per share for a total reported value of $67,447. This was a purchase (acquisition), which investors often view as a more informative/bullish signal than routine sales.

Key Details

• Transaction date: 2026-09-04; Form 4 filed: 2026-09-08 (appears to be filed within the normal reporting timeframe).
• Reported price: weighted average $3.67; underlying trade prices ranged from $3.50 to $3.70 (see footnote).
• Total shares acquired: 18,378; total reported value: $67,447.
• Post-transaction shares owned: not specified in the summary provided here — check the full Form 4 for updated beneficial ownership totals.
• Notable footnotes:
  • F1: The $3.67 is a weighted average; transactions occurred at prices between $3.50 and $3.70. The reporting person can provide a breakdown on request.
  • F2: The shares are held by YD Biopharma Holding Limited, owned through BVI entities and The E820N Trust; Dr. Shen is settlor, protector and sole beneficiary and is the beneficial owner of those shares.

Context

• This was a straight purchase (transaction code P). Purchases by executives are generally more noteworthy than sales because they signal the insider put personal capital into the company, but filings alone don’t prove intent. For full ownership details and exact per-trade breakdown, review the complete Form 4 linked by the SEC accession number.